Early intervention in high-risk smoldering myeloma with lenalidomide delays progression by up to 7 years and achieves ...

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

JNJ wins CHMP backing for Darzalex and Imbruvica in new blood cancer uses, paving the way for first-in-class approvals.

Johnson & Johnson has new data showing that combining two of its multiple myeloma therapies – Talvey and Tecvayli – has been ...

DataM Intelligence | competitive Intelligence Explore the evolving Multiple Myeloma market: drug innovations, emerging therapies, and key p ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Twelve years ago, while coaching in the Southeastern Conference at the University of Kentucky, his life took an unexpected ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products ...

ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...

Around 1,500 people with multiple myeloma will benefit from belantamab mafodotin, used in combination with bortezomib and ...